Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Sanghoon Lee, Li Zhao, Christine Rojas, Nicholas W. Bateman, Hui Yao, Olivia D. Lara, Joseph Celestino, Margaret B. Morgan, Tri V. Nguyen, Kelly A. Conrads, Kelly M. Rangel, Robert L. Dood, Richard A. Hajek, Gloria L. Fawcett, Randy A. Chu, Katlin Wilson, Jeremy L. Loffredo, Coralie Viollet, Amir A. Jazaeri, Clifton L. DalgardXizeng Mao, Xingzhi Song, Ming Zhou, Brian L. Hood, Nirad Banskota, Matthew D. Wilkerson, Jerez Te, Anthony R. Soltis, Kristin Roman, Andrew Dunn, David Cordover, Agda Karina Eterovic, Jinsong Liu, Jared K. Burks, Keith A. Baggerly, Nicole D. Fleming, Karen H. Lu, Shannon N. Westin, Robert L. Coleman, Gordon B. Mills, Yovanni Casablanca, Jianhua Zhang, Thomas P. Conrads, George L. Maxwell, P. Andrew Futreal, Anil K. Sood*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.

Original languageEnglish
Article number107502
JournalCell Reports
Issue number2
StatePublished - 14 Apr 2020
Externally publishedYes


  • R0 resection
  • copy number
  • genomics
  • immune monitoring
  • multi-omics
  • mutation
  • neoadjuvant chemotherapy
  • ovarian cancer
  • proteome
  • transcriptome


Dive into the research topics of 'Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer'. Together they form a unique fingerprint.

Cite this